Pelareorep data at AACR: 62% ORR in pancreatic cancer; TLS formation in breast cancer

ONCOLYTICS BIOTECH INC

GOBLET cohort 1: 62% objective response rate in first-line mPDAC, more than double historical chemotherapy alone.
Patients with immune activation signature had median PFS 7.5 months vs 5.6 months for those without.
AWARE-1 breast cancer study: pelareorep drove tertiary lymphoid structure formation in select patients.
Pelareorep stimulated RAS-specific T-cell clones in gastrointestinal cancers, presented at a future meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.